文献速递前列腺癌

醋酸阿比特龙联合前列腺床放疗及促黄体生成素释放激素激动剂治疗前列腺切除术后生化复发患者(CARLHA):一项2期临床试验

Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial.
PubMed 文献 · Eur Urol Oncol · 2024-05-11

这项单臂多中心2期试验纳入46例前列腺切除术后生化复发男性,给予醋酸阿比特龙联合泼尼松、挽救性前列腺床放疗及戈舍瑞林。3年生化复发无生存率(PSA≥0.2 ng/ml)为81.5%,替代生化复发无生存率(PSA≥0.5 ng/ml)为95.6%。循环肿瘤细胞计数≥5与更差生存相关,不良事件总体可控但建议密切肝脏监测。

要点

  • 3年生化复发无生存率为81.5%(95%CI 66.4-90.3%),替代生化复发无生存率为95.6%(95%CI 83.5-98.9%)。
  • 放疗相关急性不良事件最常见为尿频(41.3%),晚期不良事件最常见为尿失禁(15.2%)。
  • 循环肿瘤细胞计数≥5的患者占11%,与更差生化复发无生存相关(p=0.042)。

核心结论

  • 在挽救性放疗和戈舍瑞林基础上加用醋酸阿比特龙联合泼尼松可带来较高的生化复发无生存率和替代生化复发无生存率。
  • 不良事件总体可控,但建议密切肝脏监测。
  • 循环肿瘤细胞计数似乎是预后和预测治疗反应的有前景的生物标志物。

研究设计与样本

  • 单臂多中心2期临床试验,于2012年12月至2019年1月纳入46例前列腺切除术后生化复发男性。
  • 中位随访47个月。
  • 所有患者接受醋酸阿比特龙联合泼尼松1000 mg每日(前列腺床放疗期间750 mg)、挽救性前列腺床放疗及戈舍瑞林。

主要发现

  • 3年生化复发无生存率(PSA≥0.2 ng/ml)为81.5%(95%CI 66.4-90.3%),替代生化复发无生存率(PSA≥0.5 ng/ml)为95.6%(95%CI 83.5-98.9%)。
  • 放疗相关急性不良事件(所有级别)最常见为尿频(41.3%),晚期不良事件(所有级别)最常见为尿失禁(15.2%),3-4级急性或晚期放疗相关不良事件罕见。
  • 非放疗相关不良事件最常见为潮热(76%)、高血压(63%)和肝细胞溶解(50%,其中20%为3-4级)。
  • 11%的患者循环肿瘤细胞计数≥5,与更差的生化复发无生存相关(p=0.042)和替代生化复发无生存相关(p=0.008)。
  • 循环肿瘤细胞计数与更高复发率的关联独立于基线PSA水平和PSA倍增时间(p分别为0.42和0.09)。

临床怎么用

  • 作者认为,在挽救性放疗和戈舍瑞林基础上加用醋酸阿比特龙联合泼尼松可带来较高的生化复发无生存率和替代生化复发无生存率。
  • 作者建议密切肝脏监测。
  • 作者认为循环肿瘤细胞计数似乎是预后和预测治疗反应的有前景的生物标志物。

局限性

  • 本研究为非随机研究,患者数量有限,且报告的临床事件较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy. OBJECTIVE: To evaluate the combination of abiraterone acetate plus prednisone (AAP), prostate bed radiotherapy (PBRT), and goserelin in biochemically relapsing men after prostatectomy, and to investigate the utility of CTCs. DESIGN, SETTING, AND PARTICIPANTS: In this single-arm multicenter phase 2 trial, 46 biochemically relapsing men were enrolled between December 2012 and January 2019. The median follow-up was 47 mo. INTERVENTION: All patients received AAP 1000 mg daily (but 750 mg during PBRT), salvage PBRT, and goserelin. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was 3-yr biochemical recurrence-free survival (bRFS) when prostate-specific antigen (PSA) levels were ≥0.2 ng/ml. The secondary outcomes included alternative bRFS (alt-bRFS) when PSA levels were ≥0.5 ng/ml and safety assessment. CTC count was assessed. RESULTS AND LIMITATIONS: The 3-yr bRFS and alt-bRFS were 81.5% (95% confidence interval or CI [66.4-90.3%]) and 95.6% (95% CI [83.5-98.9%]), respectively. The most common acute radiotherapy-related adverse effect (AE; all grades was pollakiuria (41.3%). The most common late AE (all grades) was urinary incontinence (15.2%). Grade 3-4 acute or late radiotherapy-related AEs were scarce. Most frequent AEs nonrelated to radiotherapy were hot flashes (76%), hypertension (63%), and hepatic cytolysis (50%, of which 20% were of grades 3-4). Of the patients, 11% had a CTC count of ≥5, which was correlated with poorer bRFS (p = 0.042) and alt-bRFS (p = 0.008). The association between CTC count and higher rates of relapse was independent of the baseline PSA level and PSA doubling time (p = 0.42 and p = 0.09, respectively). This study was nonrandomized with a limited number of patients, and few clinical events were reported. CONCLUSIONS: Adding AAP to salvage radiation therapy and goserelin resulted in high bRFS and alt-bRFS. AEs remained manageable, although a close liver surveillance is advised. CTC count appears as a promising biomarker for prognosis and predicting response to treatment. PATIENT SUMMARY: Our study was a phase 2 clinical trial that exhibited the efficacy and tolerance of a novel androgen-receptor targeting agent (abiraterone acetate plus prednisone) in patients with prostate cancer who experienced rising prostate-specific antigen after radical prostatectomy, in combination with prostate bed radiotherapy. The results also indicated the feasibility and potential value of circulating tumor cell detection, which constitutes a possible advance in managing prostate cancers.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ah-Thiane L, Campion L, Allouache N, et al. Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial. Eur Urol Oncol. 2024. PMID: 38734543. doi:10.1016/j.euo.2024.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。